Ross Naima, Suresh Sunitha C, Dude Annie
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Chicago Medicine, 5841 S. Maryland Ave., MC 2050, Chicago, IL, 60637; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Chicago Medicine, 5841 S. Maryland Ave., MC 2050, Chicago, IL, 60637; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Am J Obstet Gynecol MFM. 2022 Mar;4(2):100544. doi: 10.1016/j.ajogmf.2021.100544. Epub 2021 Dec 4.
Respiratory distress syndrome (RDS) is a common cause of morbidity in preterm neonates. Late preterm births (34 0/7 to 36 6/7 weeks of gestation) account for three-quarters of preterm births. Delivery in the late preterm period is a well-established risk factor for RDS. Whether history of a neonate with respiratory morbidity at birth relates to respiratory morbidity in a subsequent pregnancy is not well characterized. In this research letter, we have described how maternally reported respiratory morbidity in a neonate in a previous pregnancy is associated with respiratory morbidity in a neonate in a subsequent pregnancy.
This was a secondary analysis of a randomized controlled study of antenatal corticosteroids in the late preterm period (antenatal betamethasone for women at risk for late preterm delivery). Multiparous patients with a singleton pregnancy were included. The institutional review board at The University of Chicago (approval number IRB 21-0141) deemed this study exempt. Respiratory morbidity of a previous infant was maternally reported in a questionnaire specifying any "respiratory problems at birth" in their live neonates (yes or no). Major respiratory morbidity (MRM) in the current pregnancy was defined as any of the following: continuous positive airway pressure or high-flow nasal cannula for ≥12 hours in the first 72 hours of life, ventilator use in the first 72 hours of life, extracorporeal membrane oxygenation, oxygen requirement of FiO2 of ≥0.3 for ≥24 total hours in the first 72 hours of life, or stillbirth or neonatal death at <72 hours of age. This was abstracted from maternal and neonatal medical records. The presence of any respiratory morbidity (MRM, RDS, or transient tachypnea of the newborn [TTN]) was compared by history of a previous infant with any respiratory morbidity. Chi-square and Wilcoxon rank-sum tests were used for bivariable analyses, and logistic regression was performed to adjust for confounders. The analysis was repeated, stratified by any betamethasone use.
We included 1412 multiparous patients, 195 with a previous infant with maternally reported respiratory morbidity and 1217 without. RDS, MRM, and a composite of RDS, TTN, and apnea were more likely among those who had a sibling with respiratory morbidity, per maternal report (adjusted odds ratio [aOR] of RDS, 2.17 [95% confidence interval (CI), 1.28-3.70]; aOR of MRM, 1.9 [95% CI, 1.20-3.02]; aOR of RDS, TTN, and apnea, 1.85 [95% CI, 1.22-2.70]). When stratified by administration of betamethasone, the risk of MRM was only persistent in those without betamethasone use (aOR, 1.84; 95% CI, 1.00-3.39). Similarly, the risk of RDS and a composite risk of RDS, TTN, and apnea were only persistent in those without betamethasone use (aOR, 2.37 [95% CI, 1.16-4.84]; aOR, 1.82 [95% CI, 1.05-3.17]) Tables 1 and 2.
A maternally reported history of respiratory morbidity in a previous late preterm or term infant was independently associated with respiratory morbidity, including RDS, in a subsequent infant. When stratified by betamethasone use, the risk of respiratory morbidity was only persistent in those neonates without betamethasone exposure during the late preterm period.
呼吸窘迫综合征(RDS)是早产新生儿发病的常见原因。晚期早产(妊娠34 0/7至36 6/7周)占早产的四分之三。晚期早产分娩是RDS公认的危险因素。出生时患有呼吸系统疾病的新生儿病史与后续妊娠中新生儿的呼吸系统疾病之间的关系尚未得到充分描述。在这篇研究信中,我们描述了先前妊娠中母亲报告的新生儿呼吸系统疾病与后续妊娠中新生儿呼吸系统疾病之间的关联。
这是一项对晚期早产期产前使用皮质类固醇的随机对照研究(对有晚期早产风险的妇女使用产前倍他米松)的二次分析。纳入了单胎妊娠的经产妇。芝加哥大学的机构审查委员会(批准号IRB 21 - 0141)认为该研究可豁免审查。通过母亲在问卷中报告其活产新生儿是否有任何“出生时的呼吸问题”(是或否)来获取先前婴儿的呼吸系统疾病情况。当前妊娠中的主要呼吸系统疾病(MRM)定义为以下任何一种情况:出生后72小时内持续气道正压通气或高流量鼻导管吸氧≥12小时、出生后72小时内使用呼吸机、体外膜肺氧合、出生后72小时内总吸氧时间≥24小时且吸氧浓度(FiO2)≥0.3、或出生后<72小时死产或新生儿死亡。这些信息从母亲和新生儿的医疗记录中提取。比较有任何呼吸系统疾病病史的先前婴儿与有任何呼吸系统疾病的新生儿中是否存在任何呼吸系统疾病(MRM、RDS或新生儿短暂性呼吸急促[TTN])。采用卡方检验和Wilcoxon秩和检验进行双变量分析,并进行逻辑回归以调整混杂因素。按是否使用倍他米松进行分层后重复分析。
我们纳入了1412名经产妇,其中195名母亲报告其先前婴儿有呼吸系统疾病,1217名母亲报告其先前婴儿无呼吸系统疾病。根据母亲报告,有呼吸系统疾病同胞的新生儿发生RDS、MRM以及RDS、TTN和呼吸暂停的综合情况的可能性更高(RDS的调整优势比[aOR]为2.17[95%置信区间(CI),1.28 - 3.70];MRM的aOR为1.9[95%CI,1.20 - 3.02];RDS、TTN和呼吸暂停的aOR为1.85[95%CI,1.22 - 2.70])。按倍他米松使用情况分层后,仅在未使用倍他米松的新生儿中,MRM风险持续存在(aOR为1.84;95%CI,1.00 - 3.39)。同样,仅在未使用倍他米松的新生儿中,RDS风险以及RDS、TTN和呼吸暂停的综合风险持续存在(RDS的aOR为2.37[95%CI,1.16 - 4.84];RDS、TTN和呼吸暂停的aOR为1.82[95%CI,1.05 - 3.17])(表1和表2)。
母亲报告的先前晚期早产或足月婴儿的呼吸系统疾病病史与后续婴儿的呼吸系统疾病独立相关,包括RDS。按倍他米松使用情况分层后,仅在晚期早产期间未暴露于倍他米松的新生儿中,呼吸系统疾病风险持续存在。